BMS builds case for mavacamten label ahead of FDA decision

BMS builds case for mavacamten label ahead of FDA decision

Source: 
Pharmaforum
snippet: 

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug, acquired as part of its $13.1 billion takeover of MyoKardia in 2020.